Document ZBq3DR6wKp7JR4R0E5KXK33m0

DownloadSearchable PDFRandom document
Shanghai Health Study Letterhead February _ _, 2007 DRAFT Via U.S. MAIL Richard Irons, PhD, DABT Principal Investigator, Shanghai Health Study University of Colorado Health Sciences Center 4200 East 9th Avenue, C238 Denver, CO 80262 Re: Supplemental Funding for Shanghai Study Dear Dr. Irons: I am writing on behalf of the Benzene Health Research Consortium ("BHRC"), the group of companies supporting the scientific and clinical research you are conducting in China. We appreciate your serving as a principal investigator for this unique project in Shanghai. We have considered your request for additional support, and are pleased to report that we are prepared to offer additional funding, in the amount of $6,559,864. [CORRECT AMOUNT?] We assume the substantive provisions of our original agreement will be a part of any subsequent contracts necessary to enable completion of the study. We are also providing separate and additional funding for QAlQC, as was outlined in your original proposal. As you have suggested, Dr. Jerry Rice, chair of the Scientific Review Panel for the study, as well as other colleagues, have agreed to assist in this effort. We assume the supplemental QAlQC plan, as developed by you and the Data Process Quality Assurance team, whose charter is attached, will be implemented. Please contact us if either of our assumptions are not correct. We would also appreciate receiving a contract proposal from CinPathoGen, as well as its agreements with the University of Colorado and Fudan University. Please forward at your earliest convenience. It will be necessary to have all the agreements executed and in place before the actual disbursement of funds begins. We know the additional funding is time-sensitive, and we will do what we can to expedite it. Sincerely yours, Jennifer B. Galvin, Ph.D., DABT, CIH Chair, Technical Committee Shanghai Health Study SH ELL-MCCLU RG-062055 To: From: Cc: Bcc: Received Date: Subject: Clegg, Patsy M SCC-DCS/22 <patsy.clegg@shell.com> stephen. m. bowes@exxonmobil.com <stephen. m. bowes@exxonmobil.com> brian.e.doll@exxonmobil.com <brian.e.doll@exxonmobil.com> 2007-02-1420:52:46 GMT Re: BHRC draft letter to Irons for review and response by cob Feb 14 Patsy, ExxonMobil approves. Regards, Stephen Bowes ExxonMobil Biomedical Sciences, Inc. Tel: (703) 846-1199.... Fax: (703) 846-5297.... Pager (732) 437-0999 <patsy. clegg @s hell.com> To <brian.e.doll@exxonmobil.com>, 02/14/0712:17 <jarnotb@api.org>, PM <burnetdm@bp.com>, <Mike.d.Johnston@ConocoPhillips.com> , <whiter@api.org>, <stuart.cagen@shell.com>, <ZachWong@chevrontexaco.com>, <anita. balaraman@chevrontexaco.com>, <j ennifer. b. galvin@conocophillips.co m>, <hughm7@BP.com>, <michael.g.bird@exxonmobil.com>, <Shan.Tsai@shell.com>, <stephen. m. bowes@exxonmobil.com>, <alex. yelland@chevron.com>, <myron.c.harrison@exxonmobil.com>, <heroldra@bp.com>, <trisha.m.perkins@exxonmobil.com>, <wagner@api.org>, <mfitzsim @steptoe.com> cc Subject BHRC draft letter to Irons for review and response by cob Feb 14 SH ELL-MCCLU RG-062056 Regards, Patsy Patsy Clegg Product Steward, HSSE Shell Chemical LP One Shell Plaza, 91 0 Louisiana, Houston, TX 77002-4916 Tel: +1 713241 2521 Fax: 3325 Email: patsy.clegg@shell.com Internet: http://www.shell.com/chemicals Business Success through HSSE Excellence API_ Alternative Ltr to Rlrons re Shanghai Health Study (2).ZIP (See attached file: API_ Alternative Ltr to Rlrons re Shanghai Health Study (2).ZIP) Attachments: API_ Alternative Ltr to Rlrons re Shanghai Health Study (2).ZIP SH ELL-MCCLU RG-062057 Shanghai Health Study Letterhead February _ _, 2007 DRAFT Via U.S. MAIL Richard Irons, PhD, DABT Principal Investigator, Shanghai Health Study University of Colorado Health Sciences Center 4200 East 9th Avenue, C238 Denver, CO 80262 Re: Supplemental Funding for Shanghai Health Study Dear Dr. Irons: I am writing on behalf of the Benzene Health Research Consortium ("BHRC"), the group of companies supporting the scientific and clinical research you are conducting in China, Shanghai Health Study. We appreciate your serving as a principal investigator for this unique project in Shanghai. We have considered your request for additional support, and are pleased to report that we are prepared to offer additional funding, in the amount of $6,559,864. It will be necessary to have agreements executed and in place before the actual commitment is finalized and disbursement of funds begins. [CORRECT AMOUNT?] We assume the substantive provisions of our original agreement will be a part of subsequent contracts necessary to enable completion of the study. We are also providing separate and additional funding for QAlQC, as was outlined in your original proposal. As you have suggested, Dr. Jerry Rice, chair of the Scientific Review Panel for the study, as well as other colleagues, have agreed to assist in this effort. We assume the supplemental QAlQC plan, as developed by you and the Data Process Quality Assurance team, whose charter is attached, will be implemented. Please contact us if either of our assumptions is not correct. We would also appreciate receiving your contract proposal, as well as agreements with the University of Colorado and Fudan University. Please forward at your earliest convenience. We know the additional funding is time-sensitive, and we will do what we can to expedite it. Sincerely yours, Jennifer B. Galvin, Ph.D., DABT, CIH Chair, Technical Committee Shanghai Health Study SH ELL-MCCLU RG-062058